SCYX SCYNEXIS, Inc.
Healthcare$0.73+3.00%ClosedMarket Cap: $36.8M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.90
P/S
1.81
EV/EBITDA
-0.11
DCF Value
$-3.05
FCF Yield
-16.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-119.9%
Net Margin
-120.5%
ROE
-57.2%
ROA
-31.6%
ROIC
-39.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-16.9M | $-21.3M | $— | — |
| Q4 null | $18.6M | 100.0% | $10.5M | $12.3M | $— | — |
| FY null | $20.6M | 100.0% | $-16.1M | $-8.6M | $— | — |
| Q3 null | $334.0K | 100.0% | $-8.4M | $-8.6M | $— | — |
| Q2 null | $1.4M | 100.0% | $-9.6M | $-6.9M | $— | — |
| Q1 null | $257.0K | 100.0% | $-8.6M | $-5.4M | $— | — |
| Q4 null | $977.0K | 100.0% | $-8.1M | $-4.4M | $— | — |
| FY null | $3.7M | 100.0% | $-37.1M | $-21.3M | $— | — |
| Q3 null | $660.0K | 100.0% | $-10.3M | $-2.8M | $— | — |
| Q2 null | $736.0K | 100.0% | $-9.2M | $-14.5M | $— | — |
| Q1 null | $1.4M | 100.0% | $-9.5M | $411.0K | $— | — |
| Q4 2023 | $5.8M | -153.3% | $-23.1M | $-19.6M | $-0.43 | — |